Edward B. Mulligan V Appointed to Plaintiffs’ Steering Committee in Zofran Litigation
CohenMalad, LLP partner Edward (Ned) B. Mulligan V has been appointed to the Plaintiffs’ Steering Committee for the consolidated multidistrict litigation (MDL) involving Zofran (Ondansetron) manufactured by GlaxoSmithKline. The Honorable Judge F. Dennis Saylor IV is presiding over these cases in the U.S. District Court, District of Massachusetts.
As a member of the Plaintiffs’ Steering Committee, Ned has and will continue to assist in the coordination of the pretrial proceedings in the prosecution of these personal injury claims.
Zofran (Ondansetron) earned FDA approval in 1991 for the treatment of nausea and vomiting in cancer patients, some doctors have also prescribed Zofran for off-label use to pregnant women who suffer from morning sickness. Zofran has not been approved by the FDA for use in pregnant women. Some studies have shown an association between ondansetron use and various birth defects including cleft lip, cleft palate, and heart defects.
CohenMalad, LLP attorneys have built a reputation as tough opponents in the courtroom and have a depth of experience in litigating claims for people who have been injured by dangerous drugs and medical devices. Contact us for a free case evaluation if you were prescribed ondansetron while pregnant and gave birth to a child with a cleft palate or a heart defect.
